Luspatercept - Bristol Myers Squibb
Alternative Names: ACE-536; BMS-986346; Luspatercept-aamt; REBLOZYL; ReblozylLatest Information Update: 10 Aug 2026
At a glance
- Originator Acceleron Pharma
- Developer Acceleron Pharma; Bristol-Myers Squibb; Celgene Corporation
- Class Antianaemics; Disulfides; Immunoglobulin Fc fragments; Peptides; Recombinant fusion proteins
- Mechanism of Action TGF-beta superfamily protein inhibitors
-
Orphan Drug Status
Yes - Beta-thalassaemia; Myelodysplastic syndromes
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Beta-thalassaemia; Myelodysplastic syndromes
- Preregistration Myelofibrosis
- Phase II Alpha-thalassaemia
- Discontinued Sickle cell anaemia